Oncoinvent ASA's EBIT per Share for the
six
months ended in Dec. 2025 was kr-56.04.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was kr-140.31.
During the past 3 years, the average EBIT per Share Growth Rate was 82.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 67.70% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 33.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Oncoinvent ASA's EBIT per Share or its related term are showing as below:
OSL:ONCIN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -33.9 Med: 3.2 Max: 82.8
Current: 82.8
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Oncoinvent ASA was 82.80% per year. The lowest was -33.90% per year. And the median was 3.20% per year.
OSL:ONCIN's 3-Year EBIT Growth Rate is ranked better than 97.27% of 1173
companies
in the Biotechnology industry
Industry Median: 15.4
vs OSL:ONCIN: 82.80
Oncoinvent ASA's EBIT for the
six
months ended in Dec. 2025 was kr-84.68 Mil.
Oncoinvent ASA (OSL:ONCIN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Oncoinvent ASA EBIT per Share Related Terms
Oncoinvent ASA EBIT per Share Historical Data
* Premium members only.
The historical data trend for Oncoinvent ASA's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-140.31
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoinvent ASA (OSL:ONCIN) has a EBIT per Share of kr-140.31 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Oncoinvent ASA and its competitors. According to the industry distribution chart, Oncoinvent ASA ranks #32 out of 1173 companies in the Biotechnology industry, placing it in the top 2.7%.
Is Oncoinvent ASA's EBIT per Share too high?
Oncoinvent ASA's current EBIT per Share is kr-140.31. Based on the distribution chart, Oncoinvent ASA ranks #32 out of 1173 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oncoinvent ASA has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncoinvent ASA ranks #32 out of 1173 companies for EBIT per Share. This places Oncoinvent ASA in the top 3% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Oncoinvent ASA and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncoinvent ASA's current EBIT per Share is kr-140.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Based on GuruFocus' analysis, Oncoinvent ASA (OSL:ONCIN) is currently considered Possible Value Trap. The stock's GF Value™ is kr973.15, compared to a current price of kr66.00 — trading 93.2% below its estimated fair value. The current EBIT per Share is kr-140.31. Oncoinvent ASA's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Oncoinvent ASA (OSL:ONCIN), the current EBIT per Share is kr-140.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (OSL:ONCIN) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of kr66.00 is trading 93.2% below its estimated GF Value™ of kr973.15.
GuruFocus considers Oncoinvent ASA to be Possible Value Trap.
Key valuation signals for OSL:ONCIN:
EBIT per Share: kr-140.31
GF Value™: kr973.15 vs. price of kr66.00 (93.2% below fair value)
No single metric tells the full story. See the OSL:ONCIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
37GF Score
Get the complete analysis for OSL:ONCIN
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:ONCIN has been successfully added to your 
